Gain Therapeutics Posts Encouraging Preclinical Data From Parkinson's, Alzheimer's Programs

  • Gain Therapeutics Inc GANX has presented new preclinical data from its Parkinson's and Alzheimer's Disease programs. 
  • These results were highlighted at the International Conference on Alzheimer's (AD) and Parkinson's Diseases (PD). 
  • The data shows that improving the lysosomal function through enhanced glucocerebrosidase (GCase) levels and activity can improve key pathological features in α-synucleinopathies and AD.
  • Related: Gain Therapeutics Stock Surges On Positive Preclinical Readout For Neurodegenerative Disease Drugs.
  • Orally bioavailable and brain-penetrant lead structurally targeted allosteric regulators (STARs) reduce neurotoxicity derived from the accumulation of toxic oligomeric species of Aβ and α-synuclein.
  • In mouse models, treatment with the STAR small molecule resulted in a decrease in neurotoxicity, motor deficit, neuroinflammation, and increase of neuronal survival.
  • Price Action: GANX shares are up 3.94% at $3.43 during the market session on the last check Tuesday.
Loading...
Loading...
GANX Logo
GANXGain Therapeutics Inc
$2.0513.3%

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings
Edge Rankings
Momentum
28.77
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In:
Comments
Loading...